Paul Finger

Dr. Paul T. Finger
Born November 26th, 1955
New York, NY
Education Tulane University, Tulane University School of Medicine
Years active 23
Known for Inventing new treatments, EYECANCERBIG

Medical career

Profession Ophthalmologist
Institutions New York Eye and Ear Infirmary, NYU School of Medicine
Specialism Oncology (Cancer)
Research Melanomas, Macular Degeneration
Notable prizes America's Best Doctors 2008

Paul T. Finger, MD, FACS, is an ophthalmologist in New York, New York specializing in ocular oncology.[1] Dr. Finger has pioneered the use of palladium-103 plaque radiation to treat choroidal melanoma and 3D and high-frequency ultrasound to image intraocular tumors.[2]

Education

Dr. Finger received his medical doctorate from Tulane Medical School in 1982. He completed his residency at Manhattan Eye, Ear and Throat Hospital, and his fellowship in ocular oncology at North Shore Hospital in Manhasset, New York.[3]

He is now a Clinical Professor of Ophthalmology at NYU School of Medicine.[3]

Career

Dr. Finger is certified by the American Board of Ophthalmology and is a Fellow of both the American College of Surgeons and the American Academy of Ophthalmology and treats patients from around the world.[2]

His research has focused on melanoma of the choroid, ciliary body and iris. He has written extensively about new ways to detect and treat retinoblastoma, conjunctival melanoma,[4] squamous carcinoma, metastatic cancer to the eye and orbital tumors.[5]

He has helped produce multiple medical textbooks on age-related macular degeneration and eye cancer.[6]

Prevention Campaign

Under the slogan, "Think of sunglasses as sunblock for your eyes," Dr. Finger has campaigned on television to increase the use of sunglasses in order to prevent eye cancers before they happen.[7]

EYECANCERBIG (Bio-informatics Grid)

Dr. Finger is spearheading a project by the American Joint Committee on Cancer and the International Union Against Cancer to create a common terminology and set of standards to pool treatment data from eye cancer specialists around the world. This promises to bring major breakthroughs in evaluating competing treatment regimes, and allow doctors to more easily communicate their research to one another.[8]

See also

References

External links

This article is issued from Wikipedia - version of the 10/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.